The aim of this study was to evaluate the efficacy and tolerability of febuxostat in renal transplant recipients who were previously treated with allopurinol (the daily oral dose is 100 mg). A 6-month cohort study was conducted with 46 renal transplant recipients who had hyperuricemia. In 22 patients, treatment was changed from allopurinol to febuxostat (febuxostat was given at an oral dose of 20 mg once a day), and the other 24 patients continued the allopurinol treatment (the daily oral dose is 100 mg). The serum levels of uric acid (UA), creatinine, other biochemical parameters, estimated glomerular filtration rate (eGFR), and adverse events were measured at baseline as well as at 1, 3, and 6 months after the switch to febuxostat. Serum UA levels significantly decreased from 470.82 ± 34.37 to 378.77 ± 51.97 μmol/L in the febuxostat group, and decreased from 469.46 ± 33.47 to 428.21 ± 23.37 μmol/L in the allopurinol group. The eGFR increased from 75.55 to 85.23 mL/min in the febuxostat group, and decreased from 78.79 to 70.31 mL/min in the allopurinol group. In renal transplant recipients, febuxostat reduced the serum UA levels resulting in minor short-term improvement of renal function with no changes in the other biochemical parameters.
19 October 2021 in Primary Health Care Research & Development
Background: The incidence of gout has increased rapidly in recent years, and the suspected lack of awareness of gout among general practitioners may lead to misdiagnosis and inappropriate treatment. Aim: To assess general practitioners’ management of gout at community health service clinics in the Tongzhou district of Beijing, as well as the factors that contributed to optimal decision making. Methods: A survey based on current guidelines for assessment and management of gout was sent to 245 general practitioners at community health service clinics in the Tongzhou district of Beijing. The questionnaire included personal information of general practitioners and ten items that addressed knowledge of gout. Our questionnaire was self-administered and distributed electronically via WeChat, and data were collected on a platform called ‘Wenjuanwang’. Statistical analysis was performed using SPSS version 19.0 software. Results: Totally, 216 general practitioners responded to the survey. About three-quarters (71.8%) reported having received Continuing Medical Education (CME) about gout. More than half (54.6%) reported an awareness of treat to target (T2T) for gout. However, the overall rate of good understanding of gout was only 6.5%, a basic knowledge of gout was 55.6%, and understanding about gout diagnosis and treatment was only 11.1%. The general practitioners’ understanding of basic concepts related to gout indicated that CME could improve their understanding (P < 0.05). An analysis of the general practitioners’ rate of comprehension of gout diagnosis and treatment showed that education level, CME, and familiarity with T2T could improve understandings of gout diagnosis and treatment (P < 0.05). Conclusion: There are serious deficits in understandings about gout among general practitioners in the Tongzhou district of Beijing. Quality CME is needed to improve Chinese general practitioners’ management of gout.
Aims: To analyze the clinical characteristics and identify factors associated with cardiovascular involvement in patients with relapsing polychondritis (RP). Methods: A total of 105 RP patients were enrolled and divided into cardiac and non-cardiac groups. Demographic, clinical, and serological data were collected and analyzed comparatively. Univariate and Firth's logistic regression analyses were performed to identify independent factors associated with cardiac involvement. Hierarchical clustering was applied to explore phenotypic patterns. Results: Among the RP cohort, 29.5% (31/105) exhibited cardiovascular involvement, with a male-to-female ratio of 16:15 and a mean age of 57.87 ± 12.06 years. Manifestations included aortic root dilatation (11.4%), conduction abnormalities (8.6%), myocarditis (7.6%), pericarditis (5.7%), and valvular dysfunction (3.8%). Patients with cardiac involvement exhibited a significantly lower prevalence of ocular involvement (12.9 vs. 36.5%; P = 0.016) and a non-significant trend toward lower frequency of costochondritis (9.7 vs. 24.3%; P = 0.087). Notably, low-density lipoprotein (LDL) levels were significantly lower in the cardiac involvement group [2.60(1.00, 4.37) vs. 2.84(1.45, 5.30) mmol/L; P = 0.041]. Firth's logistic regression identified the ocular involvement (OR: 0.22, 95% CI: 0.06–0.78; P = 0.010), costochondritis (OR: 0.26, 95% CI: 0.07–0.99; P = 0.029), and LDL levels (OR: 0.51, 95% CI: 0.27–0.93; P = 0.017) as independent factors associated with cardiac involvement. Clustering analysis identified five phenotypic groups, with the “tracheobronchi-cardiac” cluster showing the lowest LDL levels and the smallest proportions of ocular and costal cartilage involvement. Conclusions: Cardiac involvement in RP is not rare and is independently associated with lower LDL levels and reduced frequencies of ocular and costal cartilage involvement. These findings may help identify RP patients at risk for cardiac manifestations and suggest potential protective roles of certain clinical features.